Home LiteratureArticle Details
PMID: 16093429 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Murine double minute 2 as a therapeutic target for radiation sensitization of lung cancer.

Molecular cancer therapeutics ·Vol. 4 ·No. 8 ·2005-08-00 ·Pages 1137-45

Cao C, Shinohara ET, Niermann KJ, Donnelly EF, Chen X, Hallahan DE, Lu B

Abstract

Murine double minute 2 (MDM2) inhibits p53-mediated functions, which are essential for therapies using DNA-damaging agents. The purpose of this study was to determine whether MDM2 inhibition enhances the radiosensitivity of a lung cancer model. The effects of MDM2 inhibition on tumor vasculature were also studied. Transient transfection of H460 lung cancer cells and human umbilical vascular endothelial cells (HUVEC) with antisense oligonucleotides (ASODN) against MDM2 resulted in a reduced level of MDM2 and increased levels of p21 and p53. Clonogenic assays showed that inhibition of MDM2 greatly decreased cell survival following irradiation. Quantification of apoptotic cells by 7-aminoactinomycin D staining and of senescent cells by X-gal staining showed that both processes were significantly increased in H460 cells treated with MDM2-specific ASODN and radiation. H460 xenografts that were treated with MDM2 ASODN plus radiotherapy also showed significant growth delay (P < 0.001) and increased apoptosis by terminal deoxynucleotidyl transferase-mediated nick end labeling staining. HUVECs transfected with MDM2-specific ASODN showed impaired viability and migration with decreased tube formation. Doppler studies showed that tumor blood flow was compromised when H460 xenografts were treated with MDM2-specific ASODN and radiation. A combination of radiotherapy and inhibition of MDM2 through the antisense approach results in improved tumor control in the H460 lung cancer model. This implies that a similar strategy should be investigated among patients with locally advanced lung cancer, receiving thoracic radiotherapy.

MeSH Terms
Animals Apoptosis/genetics Cell Cycle Proteins/metabolism Cellular Senescence/genetics Cyclin-Dependent Kinase Inhibitor p21 Endothelium, Vascular/cytology,radiation effects Humans Lung Neoplasms/blood supply,genetics,radiotherapy Mice Nuclear Proteins/antagonists & inhibitors,genetics Oligonucleotides, Antisense/genetics,therapeutic use Proto-Oncogene Proteins/antagonists & inhibitors,genetics Proto-Oncogene Proteins c-mdm2 Radiation-Sensitizing Agents Transfection Tumor Cells, Cultured Tumor Suppressor Protein p53/metabolism Umbilical Cord/cytology Up-Regulation
Chemicals
CDKN1A protein, human Cdkn1a protein, mouse Cell Cycle Proteins Cyclin-Dependent Kinase Inhibitor p21 Nuclear Proteins Oligonucleotides, Antisense Proto-Oncogene Proteins Radiation-Sensitizing Agents Tumor Suppressor Protein p53 MDM2 protein, human Mdm2 protein, mouse Proto-Oncogene Proteins c-mdm2
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Cao Carolyn
Department of Radiation Oncology, Vanderbilt University, 1301 22nd Avenue South, B-902 The Vanderbilt Clinic, Nashville, TN 37232-5671, USA.
Shinohara Eric T
Niermann Kenneth J
Donnelly Edwin F
Chen Xinping
Hallahan Dennis E
Lu Bo
Article Info
Journal
Molecular cancer therapeutics
Abbr.
Mol Cancer Ther
ISSN
1535-7163
Published
2005-08-00
Pages
1137-45
Language
English
Region
United States
NLM ID
101132535
Subset
IM
Grants
NCI NIH HHS · R01-CA88076 · United States
NCI NIH HHS · R01-CA89674 · United States
NCI NIH HHS · T-32 CA93240 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com